Vantage Investment Partners LLC Purchases Shares of 147000 Gilead Sciences, Inc. (GILD)

Joan Terry
July 15, 2017

Davy Asset Ltd invested in 29,949 shares or 0.45% of the stock. Parnassus Investments CA boosted its position in shares of Gilead Sciences by 37.4% in the first quarter. The stock rose 0.16% or $0.11 reaching $70.69. About shares traded. Brinker International, Inc. It has underperformed by 38.50% the S&P500. DBD's SI was 10.65 million shares in July as released by FINRA. Its up 9.44% from 10.79 million shares previously. Over the short term, some market observers may have noticed that It has a 0.91% short float with 15 days to cover. It is down 21.80% since July 14, 2016 and is downtrending. It has underperformed by 15.53% the S&P500.

Gilead Sciences earned a media sentiment score of 0.17 on Accern's scale. Its down 0.98, from 3.19 in 2016Q3.

Amica Retiree Medical Trust continued to hold its stake in shares of Gilead Sciences, Inc.

Lucas Capital Management raised its position in Gilead Sciences, Inc. The biopharmaceutical company reported $2.20 earnings per share for the quarter, topping the consensus estimate of $2.18 by $0.02. Bright Rock Capital Lc holds 106,000 shares or 2.35% of its portfolio. Berenberg initiated Gilead Sciences, Inc. (NASDAQ:GILD). Calamos Wealth Management Ltd Liability Com, Illinois-based fund reported 33,727 shares.

Seizert Capital Partners Llc decreased Lear Corp Com New (NYSE:LEA) stake by 4,136 shares to 55,305 valued at $7.32 million in 2016Q4. Winslow Evans & Crocker accumulated 358 shares or 0% of the stock. First Republic Invest Inc owns 451,843 shares or 0.28% of their USA portfolio. (NASDAQ:GILD). Moreover, Stock Yards Retail Bank has 0.99% invested in Gilead Sciences, Inc. Riverpoint Cap Mgmt has invested 0.03% in Gilead Sciences, Inc. (NASDAQ:GILD). Wade G W & invested in 0.14% or 12,180 shares. 1832 Asset Limited Partnership accumulated 777,569 shares. Moreover, Private Advisor Group Inc has 0.22% invested in Gilead Sciences, Inc.

Since February 1, 2017, it had 0 insider purchases, and 10 sales for $28.29 million activity. MARTIN JOHN C sold $4.78M worth of Gilead Sciences, Inc. WILSON GAYLE E sold $1.41 million worth of stock or 20,365 shares. Shares for $668,667 were sold by Cogan John Francis on Tuesday, May 9.

Wimbledon | Federer first man to reach 11 finals at same Slam
After losing in the Wimbledon semifinals past year , he took the rest of 2016 off to let his surgically repaired left knee heal. It was after the first of his five Australian Opens in 2004 that he claimed the world number one ranking for the first time.

In other news, EVP Gregg H. Alton sold 5,000 shares of the business's stock in a transaction dated Monday, July 3rd. One equities research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating, fourteen have issued a buy rating and two have given a strong buy rating to the stock. Therefore 66% are positive. J P Morgan Chase & Co restated an "overweight" rating and set a $82.00 price target on shares of Gilead Sciences in a research report on Thursday, April 6th. Finally, Robert W. Baird reissued an "outperform" rating and issued a $87.00 target price on shares of Gilead Sciences in a research report on Thursday. The firm has "Hold" rating given on Tuesday, July 11 by Jefferies. On Friday, January 8 the stock rating was upgraded by IBC to "Sector Outperform". Jefferies maintained the stock with "Buy" rating in Monday, June 12 report. Oppenheimer maintained Gilead Sciences, Inc. (NASDAQ:GILD) rating on Wednesday, August 31. Citigroup has "Buy" rating and $105 target. The rating was downgraded by Maxim Group on Friday, April 29 to "Hold". The firm earned "Outperform" rating on Wednesday, February 3 by RBC Capital Markets. After $2.20 actual EPS reported by Gilead Sciences, Inc. for the previous quarter, Wall Street now forecasts -3.18% negative EPS growth. (NASDAQ:GILD) to report earnings on July, 24. The biopharmaceutical company reported $2.20 EPS for the quarter, beating analysts' consensus estimates of $2.18 by $0.02. The expected GILD's profit could reach $2.81 billion giving the stock 8.29 P/E in the case that $2.13 earnings per share is reported.

Tekla Capital Management Llc decreased Gilead Sciences Inc.

Here are a few additional firms who have increased or decreased their stake in (GILD). Renaissance Technologies LLC now owns 5,274,948 shares of the biopharmaceutical company's stock worth $377,739,000 after buying an additional 3,327,900 shares during the period. Vanguard Reit Etf (VNQ) was raised too.

Investors sentiment increased to 0.8 in Q4 2016. Its down 1.19, from 2.38 in 2016Q3. More interesting news about Gilead Sciences, Inc. The value of the position overall is up by 4.2%.

WARNING: This report was originally posted by Community Financial News and is owned by of Community Financial News. Insperity Inc. now has $1.51 billion valuation. Wesbanco Financial Bank Inc reported 0.11% stake. 10 are owned by Redwood Invests Llc. Blackrock holds 0.02% or 910,087 shares. Murphy Management reported 9,995 shares. Franklin Resource holds 14.32 million shares or 0.53% of its portfolio. Pnc Svcs Grp Inc reported 0% in Diebold Nixdorf Inc (NYSE:DBD). It also upped Charles Schwab Corporation (NYSE:SCHW) stake by 18,100 shares and now owns 26,875 shares. Acropolis Ltd holds 0.22% or 16,355 shares in its portfolio. The Seizert Capital Partners Llc holds 605,027 shares with $43.33 million value, up from 597,128 last quarter. Therefore 30% are positive. Silver Wheaton Corp. had 27 analyst reports since August 12, 2015 according to SRatingsIntel. On Friday, July 24 the stock rating was maintained by Piper Jaffray with "Overweight". As per Wednesday, November 2, the company rating was upgraded by BMO Capital Markets. The company was maintained on Wednesday, April 19 by Feltl Co. (NASDAQ:GILD) rating on Wednesday, February 3. Mizuho has "Buy" rating and $88 target. The firm has "Equal-Weight" rating by Morgan Stanley given on Thursday, May 26. The company was maintained on Thursday, February 4 by Wedbush. The firm has "Buy" rating given on Tuesday, June 7 by Maxim Group. Parnassus Investments sold 70,130 shares as Insperity Inc.

Diebold Nixdorf, Incorporated provides connected commerce services, software and technology. It operates through four geographic divisions: North America, which consists of the United States and Canada; Latin America, which includes its markets in Mexico, the Caribbean, Central America and South America; Europe, the Middle East and Africa, and Asia Pacific, which consists of its markets in Asia, Australia and New Zealand.

Other reports by BadHub

Discuss This Article